BIVICTRIX THERAPEUTICS LIMITED

• ⚠

  Material uncertainty over going concern

  Shareholders should be aware that such conditions represent a material uncertainty which may cast significant doubt on the Group and Company's ability to continue as a going concern and, therefore, it may be unable to realise its assets and discharge its liabilities in the normal course of business.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. BIVICTRIX THERAPEUTICS LIMITED 2024-09-18 → present
2. BIVICTRIX THERAPEUTICS PLC 2021-08-05 → 2024-09-18
3. BIVICTRIX PLC 2021-06-22 → 2021-08-05

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Shareholders should be aware that such conditions represent a material uncertainty which may cast significant doubt on the Group and Company's ability to continue as a going concern and, therefore, it may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. BIVICTRIX THERAPEUTICS LIMITED · parent
   1. BiVictriX Limited 100% · England & Wales · research and development

Significant events

• “Identifying our lead therapeutic candidate for BVX002, demonstrating very promising anti-tumour activity and tolerability in an animal model of Ovarian Cancer.”
• “Filing two patents providing broad protection for the targeted antigen pair and specific antibody sequences used for BVX002.”
• “Securing Orphan Drug Designation status for BVX001.”
• “Dose-dependent anti-tumour activity with BVX001 across a diverse range of patient samples with CD7+CD33+ AML.”
• “Completing a comprehensive toxicity assessment of BVX001 (non-GLP) in an animal species, demonstrating the superior safety and tolerability of BVX001 versus competitor ADC approaches using the same toxic warhead.”
• “On 2 May 2025, the company entered into subscription and underwriting agreements with three shareholders under which the shareholders agreed to underwrite £500,000 of a proposed placing of £800,000.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

1

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -70.8%

  £3,279,000 → £957,000

• Net assets

  -61.9%

  £3,537,000 → £1,348,000

• Employees

  0%

  17 → 17

• Operating profit

  +11.4%

  -£3,025,000 → -£2,681,000

• Profit before tax

  +11.5%

  -£3,003,000 → -£2,657,000

• Wages

  -19.1%

  £967,000 → £782,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers